# Semaglutide Treatment On Coronary Progression

Study · id `cardio:ct-nct03985384` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03985384](<https://clinicaltrials.gov/study/NCT03985384>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03985384

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

## Technical summary

Registry record NCT03985384. Randomized; quadruple masking; primary purpose treatment. Start 2019-04-30 (actual); primary completion 2022-12-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 140 participants (enrolled count; ClinicalTrials.gov record NCT03985384, source copy `cardio:ctgov-nct03985384-2023-10-05`, retrieved 2026-10-26)
- Started: 2019-04-30 (actual) (ClinicalTrials.gov record NCT03985384, source copy `cardio:ctgov-nct03985384-2023-10-05`, retrieved 2026-10-26)
- Primary completion: 2022-12-27 (actual) (ClinicalTrials.gov record NCT03985384, source copy `cardio:ctgov-nct03985384-2023-10-05`, retrieved 2026-10-26)
- Completion: 2022-12-27 (actual) (ClinicalTrials.gov record NCT03985384, source copy `cardio:ctgov-nct03985384-2023-10-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03985384, source copy `cardio:ctgov-nct03985384-2023-10-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03985384-2023-10-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Semaglutide Treatment On Coronary Progression
- Acronym: STOP
- Condition: Type 2 Diabetes
- Condition: Coronary Artery Disease
- Intervention (Drug): Semaglutide 2 MG/1.5 ML Subcutaneous Solution
- Intervention (Drug): Placebo
- Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (`cardio:org-lundquist-institute-for-biomedical-innovation-at-harbor-439991`)

## Provenance

Content hash: 401212d22d9f10deb51cba66729931d784a2b6bc32b030ad28a08cff85acd3fc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
